People: Genentech Vice President For Science Moves To Stanford University As Genetics Chairman

David Botstein, a former vice president for science at Genentech Inc., a South San Francisco, Calif., biotechnology company, is the new chairman of the genetics department at Stanford University. He began in the post August 1. A native of Switzerland, Botstein is internationally recognized for his contributions to the search for the human gene blueprint. He is credited with helping to develop the technique of using restriction fragment length polymorphisms (RLFPs) as genetic markers, thus allo

Written byJulia King
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

David Botstein, a former vice president for science at Genentech Inc., a South San Francisco, Calif., biotechnology company, is the new chairman of the genetics department at Stanford University. He began in the post August 1.

A native of Switzerland, Botstein is internationally recognized for his contributions to the search for the human gene blueprint. He is credited with helping to develop the technique of using restriction fragment length polymorphisms (RLFPs) as genetic markers, thus allowing the identification of mutant gene products responsible for genetic diseases. Over the last 20 years his research has encompassed almost the entire field of genetics, including studies on bacteria and the human genome.

Before joining Genentech, Bot-stein served on the biology faculty at the Massachusetts Institute of Technology, first as an associate professor of genetics and later as a full professor. He left MIT in 1988 to work in private industry.

Commenting on his ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies